CVKDCadrenal Therapeutics, Inc. Common Stock
The schedule
- Thu15Oct
By mid-October 2026, the market will be watching for a dilutive equity raise or ATM utilization to extend CVKD’s cash runway. If management executes a modestly sized financing with supportive terms and credible use-of-proceeds, shares could stabilize back toward $1.90; if the raise is deeply discounted or signals more severe funding stress, the stock could trade down toward $1.90 as dilution risk is repriced.
- Mon8Feb
The Q3 2026 earnings release on 2026-11-12 will update investors on CVKD’s cash position after any financing activity and ongoing burn. Clear visibility to at least one year of funding and disciplined spending could help the stock grind back toward $1.00, while signs of continued high burn or insufficient proceeds could push shares toward $1.00 by mid-December.
- Mon10May
Q4 2026 earnings in mid-February 2027 should provide an updated view of CVKD’s clinical pipeline strategy and spending plans into 2027. If management can articulate clear upcoming catalysts for its cardiovascular program while keeping operating expenses in check, the stock could recover toward $0.70; if timelines slip or costs rise without new funding clarity, shares could drift down toward $0.70 into mid-March.
- Mon9Aug
By the Q1 2027 earnings release around 2027-05-13, CVKD’s share price and corporate actions will be evaluated against listing compliance and broader strategic options. Evidence of progress toward value-creating milestones or steps to protect the listing could pull the stock toward $0.45, while continued pressure on the share price and limited strategic progress could see it trade closer to $0.15 by mid-June.
Past
- Mon10Aug
Actual outcome: Bear · $1.22 at outcome
Cadrenal Therapeutics reported Q2 EPS that met estimates at -$1.04 and highlighted late-breaking Phase 2 CAD-1005 data alongside an ongoing strategic partnering process. Despite these clinical updates, the lack of concrete financing developments or a finalized partnership left investors concerned about the company's cash runway, driving a 9.3% decline in the stock.
Q2 2026 earnings and cash runway commentary on 2026-08-10, with the stock oversold around $1.96 and investors focused on burn rate and any progress in the cardiovascular pipeline. A constructive update on financing visibility or trial timelines could support a rebound toward $2.50, while weaker runway or a more urgent financing message could pull shares toward $2.50 into early September.